Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 10/20 | 0.43 |
| ▸ | ACHE | P22303 | 10/20 | 0.43 |
| ▸ | TACR1 | P25103 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7006162 | 1.00 | KMT2A (0.45) | KMT2AMEN1CRHBPCRHR2BCHE | |
| SCHEMBL6342999 | 0.95 | KMT2A (0.40) | KMT2AMEN1CRHBPCRHR2BCHE | |
| SCHEMBL6336912 | 0.95 | KMT2A (0.40) | KMT2AMEN1CRHBPCRHR2BCHE | |
| SCHEMBL6336995 | 0.82 | PARP1 (0.47) | KMT2AMEN1CRHBPCRHR2BCHE | |
| SCHEMBL6333422 | 0.82 | PARP1 (0.47) | KMT2AMEN1CRHBPCRHR2BCHE | |
| SCHEMBL6540897 | 0.81 | MEN1 (0.46) | KMT2AMEN1CRHBPCRHR2BCHE | |
| SCHEMBL6635272 | 0.78 | PARP1 (0.45) | KMT2AMEN1CRHBPCRHR2 | |
| SCHEMBL7204176 | 0.77 | ALDH1A1 (0.44) | KMT2AMEN1CRHBPCRHR2BCHE | |
| SCHEMBL6341433 | 0.77 | ALDH1A1 (0.44) | KMT2AMEN1CRHBPCRHR2BCHE | |
| SCHEMBL6906749 | 0.75 | MEN1 (0.41) | KMT2AMEN1CRHBPCRHR2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171350-A1 | Benzhydryl derivatives | FUJISAWA PHARAMACEUTICAL CO., LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| US-20040220403-A1 | 1-(2-Methoxybenzyl)-3-benzhydrylpiperazines as tachykinin anatgonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-04 | — | — | US | disclosed |
| EP-1456201-A1 | BENZHYDRYL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-15 | — | — | EP | disclosed |
| EP-1368343-A1 | 1-(2-METHOXYBENZYL)-3-BENZHYDRYLPIPERAZINES AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-10 | — | — | EP | disclosed |
| WO-2003053957-A1 | BENZHYDRYL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (US) | 2003-07-03 | — | — | WO | disclosed |
| WO-2002055518-A1 | 1-(2-METHOXYBENZYL)-3-BENZHYDRYLPIPERAZINES AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171350-A1 | Benzhydryl derivatives | BDKRB1, BDKRB2, TACR1 | KMT2A 2775/4885MEN1 550/4885CRHBP 1459/4885 |
| US-20040220403-A1 | 1-(2-Methoxybenzyl)-3-benzhydrylpiperazines as tachykinin anatgonists | BDKRB1, BDKRB2, TACR1 | KMT2A 1539/4885MEN1 442/4885CRHBP 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.